Nitinotes, developer of EndoZiptm, a fully automated endoscopic suturing system aimed at treating obesity, today announced that clinical research on the EndoZiptm system will be presented at upcoming ...
Nitinotes, developer of EndoZip™, a fully automated endoscopic suturing system aimed at treating obesity, today announced that clinical research on the EndoZip™ system will be presented at upcoming ...
Presenter: Amy Paller, M.S., M.D., Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and ...
VG-3927 showed a predictable and dose-dependent pharmacokinetic (PK) profile that supports once-daily dosing. These data ...
Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...
Clinical researcher Nadine Spring discusses the long-standing lack of diversity in clinical trials and why she's fighting for ...
Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...
Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...
MyChesCo on MSN4d
Context Therapeutics to Showcase CT-95 Data at AACR 2025PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced that new research on its clinical asset, CT-95, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback